C.S. Denlinger

Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study

Geoffrey Y. Ku, Georg-Martin Haag, H. Park, Vincent K. Lam et autres

BACKGROUND: Nivolumab-based therapies are efficacious with acceptable safety in patients with gastric cancer (GC) and gastroesophageal junction cancer (GEJC). Novel nivolumab-based combination immunotherapies may offer enhanced efficacy in these indications. FRACTION-GC was a signal-seeking, randomized, open-label, phase II adaptive-design trial assessing efficacy …

us, de, ca, au, il, it, ch (code pays fourni par la source)

1423P Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial

Elena Elimova, Jaffer A. Ajani, H.A. Burris, C.S. Denlinger et autres

ca, us, kr, jp, it (code pays fourni par la source)

1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)

Geoffrey Y. Ku, Elena Elimova, C.S. Denlinger, Ram Sharan Mehta et autres

us, ca, kr (code pays fourni par la source)

P2.15-C Phase 1 Trial Evaluating Safety, Efficacy, and PK of AMG 510, a Novel KRASG12C Inhibitor, in Non-Small Cell Lung Cancer

Ramaswamy Govindan, Marwan Fakih, T.J. Price, Gerald S. Falchook et autres

us, gb, au (code pays fourni par la source)

Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours

Ramaswamy Govindan, Marwan Fakih, Timothy Price, Gerald S. Falchook et autres

us, au (code pays fourni par la source)

OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC

Ramaswamy Govindan, Marwan Fakih, T.J. Price, Gerald S. Falchook et autres

us, au (code pays fourni par la source)

A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors

C.S. Denlinger, Jeffrey R. Infante, Raid Aljumaily, Aung Naing et autres

Background: MEDI1873 is a novel GITR-ligand/IgG1 agonist fusion protein that binds the co-stimulatory glucocorticoid-induced TNF receptor family-related protein (GITR) on CD4+ and CD8+ effector T cells and regulatory T cells. This Phase 1 study evaluated safety, maximum tolerated dose (MTD), pharmacokinetics (PK), …

us (code pays fourni par la source)

Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)

Wells A. Messersmith, S. Cohen, Safi Shahda, Heinz‐Josef Lenz et autres

us (code pays fourni par la source)

Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma

Matteo Simonelli, Paolo Andrea Zucali, Armando Santoro, Melanie B. Thomas et autres

it, us, kr (code pays fourni par la source)

Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally ad

C.S. Denlinger, S.J. Sym, J. C. Bendell, María Alsina et autres

Abstract P6-15-15: MM-111 - A Novel Bispecific Antibody Targeting HER-2/HER-3 Z Heterodimer: Safety and Tolerability in a First-In Human Phase I/II Study in Patients with Refractory HER2-Positive (HER-2+) Cancers

M. Beeram, C.S. Denlinger, A. W. Tolcher, LJ Goldstein et autres

Abstract Background: The ErbB2/ErbB3 oncogenic heterodimer is the most potent ErbB receptor pairing with respect to strength of interaction, receptor tyrosine phosphorylation, and downstream signaling through mitogen activated protein kinase and phosphoinositide-3 kinase pathways. ErbB3 signaling has emerged as an important mechanism …

us (code pays fourni par la source)

A phase I/II and pharmacologic study of MM-111 in patients with advanced, refractory HER2-positive (HER2+) cancers.

C.S. Denlinger, M. Beeram, A. W. Tolcher, Leonide Goldstein et autres

TPS169 Background: The ErbB2/ErbB3 oncogenic heterodimer is the most potent ErbB receptor pairing with respect to strength of interaction, ligand–induced tyrosine phosphorylation, and downstream signaling through mitogen-activated protein kinase and phosphoinositide-3 kinase pathways. Recently, ErbB3 signaling has emerged as an important hypothesized …